One-year intranasal application of growth hormone releasing peptide-2 improves body weight and hypoglycemia in a severely emaciated anorexia nervosa patient.

Haruta I, Fuku Y, Kinoshita K, Yoneda K, Morinaga A, Amitani M, Amitani H, Asakawa A, Sugawara H, Takeda Y, Bowers CY, Inui A

Journal of cachexia, sarcopenia and muscle27 Apr 2015Cited by 20 (Europe PMC)

PMID26401470PMCIDPMC4575555DOI10.1002/jcsm.12028PepBankPUB-26401470

Read at source PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanCase report or seriesEfficacy outcome
In a patient with severe anorexia nervosa, intranasal GHRP‑2 increased the feeling of hunger and food intake.
In plain wordsIn one patient with anorexia nervosa, GHRP‑2 raised hunger and food intake.
Peptide
GHRP-2
Outcome
IncreaseHunger and food intake
Study
n = 1
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated · intranasal · 1 yearAs given in this study (human).
Source sentences
Summary
GHRP-2 increased the feeling of hunger and food intake, decreased early satiety and improved hypoglycemia.
1 context sentence(design, population, supporting numbers)
Summary · context
We administered GHRP-2 to a patient with a 20-year history of anorexia nervosa to determine whether GHRP-2 treatment increases food intake and body weight. GHRP-2 was administered before every meal by an intranasal approach for 1 year.
Report a problemFND-2640147001
02HumanCase report or seriesEfficacy outcome
In a patient with severe anorexia nervosa, intranasal GHRP‑2 decreased early satiety.
In plain wordsIn one patient with anorexia nervosa, GHRP‑2 reduced early fullness at meals.
Peptide
GHRP-2
Outcome
DecreaseEarly satiety
Study
n = 1
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated · intranasal · 1 yearAs given in this study (human).
Source sentences
Summary
GHRP-2 increased the feeling of hunger and food intake, decreased early satiety and improved hypoglycemia.
1 context sentence(design, population, supporting numbers)
Summary · context
We administered GHRP-2 to a patient with a 20-year history of anorexia nervosa to determine whether GHRP-2 treatment increases food intake and body weight. GHRP-2 was administered before every meal by an intranasal approach for 1 year.
Report a problemFND-2640147002
03HumanCase report or seriesEfficacy outcome
In a patient with severe anorexia nervosa, intranasal GHRP‑2 improved hypoglycemia.
In plain wordsIn one patient with anorexia nervosa, GHRP‑2 improved low blood sugar.
Peptide
GHRP-2
Outcome
DecreaseHypoglycemia
Study
n = 1
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · intranasal · 1 yearAs given in this study (human).
Source sentences
Summary
GHRP-2 increased the feeling of hunger and food intake, decreased early satiety and improved hypoglycemia.
1 context sentence(design, population, supporting numbers)
Summary · context
We administered GHRP-2 to a patient with a 20-year history of anorexia nervosa to determine whether GHRP-2 treatment increases food intake and body weight. GHRP-2 was administered before every meal by an intranasal approach for 1 year.
Report a problemFND-2640147003
04HumanCase report or seriesEfficacy outcome
In a patient with severe anorexia nervosa, body weight gradually increased by 6.7 kg, from 21.1 kg to 27.8 kg, in 14 months after GHRP‑2 administration began.
In plain wordsOne patient with anorexia nervosa gained 6.7 kg in 14 months while using GHRP‑2.
Peptide
GHRP-2
Outcome
IncreaseBody weight
Study
n = 1
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · intranasal · 1 yearAs given in this study (human).
Measurements
Body weight change
6.7 kg
from 21.1 kg to 27.8 kg
Source sentences
Summary
The patient's body weight gradually increased by 6.7 kg (from 21.1 kg to 27.8 kg) in 14 months after starting GHRP-2 administration.
1 context sentence(design, population, supporting numbers)
Summary · context
We administered GHRP-2 to a patient with a 20-year history of anorexia nervosa to determine whether GHRP-2 treatment increases food intake and body weight. GHRP-2 was administered before every meal by an intranasal approach for 1 year.
Report a problemFND-2640147004
05HumanCase report or seriesEfficacy outcome
In a patient with severe anorexia nervosa, fatigability improved during GHRP‑2 administration.
In plain wordsOne patient with anorexia nervosa felt less tired while using GHRP‑2.
Peptide
GHRP-2
Outcome
DecreaseFatigability
Study
n = 1
Outcome group
Exercise and physical function · Whole body
Studied dose
Dose not stated · intranasal · 1 yearAs given in this study (human).
Source sentences
Summary
The fatigability and muscle strength improved, and the physical and mental activities were also increased.
1 context sentence(design, population, supporting numbers)
Summary · context
We administered GHRP-2 to a patient with a 20-year history of anorexia nervosa to determine whether GHRP-2 treatment increases food intake and body weight. GHRP-2 was administered before every meal by an intranasal approach for 1 year.
Report a problemFND-2640147005
06HumanCase report or seriesEfficacy outcome
In a patient with severe anorexia nervosa, muscle strength improved during GHRP‑2 administration.
In plain wordsOne patient with anorexia nervosa had better muscle strength while using GHRP‑2.
Peptide
GHRP-2
Outcome
IncreaseMuscle strength
Study
n = 1
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
Dose not stated · intranasal · 1 yearAs given in this study (human).
Source sentences
Summary
The fatigability and muscle strength improved, and the physical and mental activities were also increased.
1 context sentence(design, population, supporting numbers)
Summary · context
We administered GHRP-2 to a patient with a 20-year history of anorexia nervosa to determine whether GHRP-2 treatment increases food intake and body weight. GHRP-2 was administered before every meal by an intranasal approach for 1 year.
Report a problemFND-2640147006
07HumanCase report or seriesEfficacy outcome
In a patient with severe anorexia nervosa, physical and mental activities increased during GHRP‑2 administration.
In plain wordsOne patient with anorexia nervosa was more active in body and mind while using GHRP‑2.
Peptide
GHRP-2
Outcome
IncreasePhysical and mental activities
Study
n = 1
Outcome group
Exercise and physical function · Whole body
Studied dose
Dose not stated · intranasal · 1 yearAs given in this study (human).
Source sentences
Summary
The fatigability and muscle strength improved, and the physical and mental activities were also increased.
1 context sentence(design, population, supporting numbers)
Summary · context
We administered GHRP-2 to a patient with a 20-year history of anorexia nervosa to determine whether GHRP-2 treatment increases food intake and body weight. GHRP-2 was administered before every meal by an intranasal approach for 1 year.
Report a problemFND-2640147007
08HumanCase report or seriesSafety outcome
No obvious side effects were observed in a patient after long-term intranasal GHRP‑2 administration.
In plain wordsOne patient had no obvious side effects from a year of GHRP‑2 nasal spray.
Peptide
GHRP-2
Outcome
No significant changeSide effects of long-term intranasal GHRP-2
Study
n = 1
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · intranasal · 1 yearAs given in this study (human).
Source sentences
Summary
No obvious side effects were observed after long-term intranasal administration of GHRP-2.
1 context sentence(design, population, supporting numbers)
Summary · context
We administered GHRP-2 to a patient with a 20-year history of anorexia nervosa to determine whether GHRP-2 treatment increases food intake and body weight. GHRP-2 was administered before every meal by an intranasal approach for 1 year.
Report a problemFND-2640147008

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.